Reportlinker Adds Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis

Oct 19, 2010, 13:31 ET from Reportlinker

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis

http://www.reportlinker.com/p0284749/Triple-Analysis-Breast-Cancer-Colorectal-Cancer-and-Angiogenesis.html

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer

The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.

This part is based on the following publication:

Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 156 colorectal cancer drugs within the portfolio of 108 investigators, from Preclinical to Marketed. This report part extensively analyses 120 identified targets of colorectal cancer drugs, organized into 105 drug target strategies, and assesses them in colorectal cancer.

This part is based on the following publication:

Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

Part III: Angiogenesis

The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

This part is based on the following publication:

Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer

5.1 The Scope of this Report 29

6 Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441

8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891

11 Drug Index 893

12 Company Index 905

Figures: Includes 7 Figures

Tables: Includes 274 Tables

Total Number of Pages: 913

Part II: Colorectal Cancer

5 How to Use this Report 15

12 Drug Target Profiles of Colorectal Cancer Drugs (120 Drug Targets) 75-232

14 The Progression and Maturity of Colorectal Cancer Targets (105 Drug Target Strategies and 156 Drugs) 238-257

15 Targets by R&D Approach in Colorectal Cancer (8 Different Compound Strategies) 258-281

16 Colorectal Cancer Targets by Companies (108 Investigators) 282-294

18 Drug Index 296

19 Company Index 299

Figures: Includes 6 Figures

Tables: Includes 50 Tables

Total Number of Pages: 301

Part III: Angiogenesis

5.1 The Scope of this Report 35

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366

7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437

8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485

9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211

10 Disclaimer 1212

11 Drug Index 1213

12 Company Index 1221

Figures: Includes 7 Figures

Tables: Includes 300 Tables

Total Number of Pages: 1227

To order this report:

Drug Discovery and Development Industry: Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com